The 37 linked references in paper A. Zemchenkov Y., R. Gerasimchuk P., K. Novokshonv Y., Y. Karelina V., Y. Fedotov N., R. Chernikov A., I. Sleptsov V., A. Semenov A., A. Bubnov N., Александр Земченков Юрьевич, Роман Герасимчук Павлович, Константин Новокшонов Юрьевич, Юлия Карелина Валерьевна, Юрий Федотов Николаевич, Роман Черников Анатольевич, Илья Слепцов Валерьевич, А. Семенов А., Александр Бубнов Николаевич (2016) “Сравнительный анализ эффективности паратиреоидэктомии и местных инъекций активаторов рецепторов витамина D в паращитовидные железы // Comparative analysis of the parathyroidectomy and local vitamin D receptor activator injections into parathyroid glands” / spz:neicon:nefr:y:2016:i:4:p:80-92

  1. Ketteler M, Elder GJ, Evenepoel P et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015;87(3):502-528. doi: 10.1038/ki.2014.425
  2. Cattinelli I, Bolzoni E, Barbieri C et al. Use of Self Organizing Maps for Balanced Scorecard analysis to monitor the performance of dialysis clinic chains. Health Care Manag Sci 2012; 15(1): 79-90. doi: 10.1007/s10729-011-9183-6 (the paper at Socionet)
  3. Goldsmith D, Covic A, Vervloet M et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015;30(5):698-700. doi: 10.1093/ndt/gfv050
  4. Li S, Chen YW, Peng Y et al. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 2011; 57(4): 602–611. doi: 10.1053/j.ajkd.2010.10.041
  5. Akaberi S, Clyne N, Sterner G et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991 – 2009. BMC Nephrol 2014; 15:75. doi: 10.1186/1471-2369-15-75
  6. Lafrance JP, Cardinal H, Leblanc M. Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol 2013; 14: 100. doi: 10.1186/1471-2369-14-100
  7. Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012;141(1):2-18. doi: 10.1037/a0024338
  8. Kelley K, Preacher KJ. On effect size. Psychol Methods 2012;17(2):137-52. doi: 10.1037/a0028086.
  9. Hedges LV. Distribution theory for Glass’ estimator of effect size and related estimators. J of Educational Statistics 1981; 6 (2): 107–128. doi:10.3102/10769986006002107. (the paper at Socionet)
  10. Verbitskaya EV. Meta-analysis: Problems with Russian Publications. Int J Risk Saf Med 2015;27 Suppl 1:S89-90. doi: 10.3233/JRS-150702
  11. Grangé S, Hanoy M, Le Roy F et al. Monitoring of hemodialysis quality-of-care indicators: why is it important? BMC Nephrol 2013;14:109. doi: 10.1186/1471-2369-14-109
  12. Kliger AS. Quality Measures for Dialysis: Time for a Balanced Scorecard. Clin J Am Soc Nephrol 2016;11(2):363-368. doi: 10.2215/CJN.06010615
  13. Stivelman JC. Monitoring quality of care at dialysis facilities: a case for regulatory parsimony-and beyond. Clin J Am Soc Nephrol 2012; 7(10): 1673-1681. doi: 10.2215/CJN.01750212
  14. Cunningham J, Floege J, London G et al. Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus 2008;1(Suppl 1):i29-i35. doi: 10.1093/ ndtplus/sfm042.
  15. Chertow GM, Block GA, Correa-Rotter R et al. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367(26):24822494. doi: 10.1056/NEJMoa1205624
  16. Ballinger AE, Palmer SC, Nistor I et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; 12: CD006254. doi: 10.1002/14651858.CD006254.pub2
  17. Duranton F, Rodriguez-Ortiz ME, Duny Y et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 2013; 37(3): 239-248. doi: 10.1159/000346846
  18. Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008; 12 [Suppl 1]:S21-26. doi: 10.1111/j.17449987.2008.00627.x
  19. Brunkhorst R. Mineral and bone disorder in chronic kidney disease: Critical appraisal of pharmacotherapy. [Article in German] Internist (Berl) 2014; 55(3): 334-339. doi: 10.1007/ s00108-014-3447-4
  20. Кеттелер М, Мартин КД, Вольф М и др. Парикальцитол в сравнении с цинакальцетом в сочетании с низкими дозами витамина D в лечении вторичного гиперпаратиреоза у пациентов на гемодиализе: результаты исследования IMPACT SHPT. Нефрология 2012; 16(4):28-38 [Ketteler M, Martin KJ, Volf M et al. Paricalcitol compared to cinacalcet with low-dose vitamin d therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT research. Nephrology (in Rus) 2012; 16(4):28-38]
  21. Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15(3):509-520. doi: 10.3111/13696998.2012.664799.
  22. Wetmore JB, Gurevich K, Sprague S et al. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 2015;10(6):1031-1040. doi: 10.2215/CJN.07050714
  23. Sprague SM, Wetmore JB, Gurevich K et al. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 2015; 10(6): 1021-1030. doi: 10.2215/CJN.03270314
  24. Yamamoto M, Ogata H, Mizobuchi M et al. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clin Exp Nephrol 2012; 16(2): 292-299. doi: 10.1007/s10157-011-0547-5
  25. Chen J, Zhou QY, Wang JD. Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure: A meta-analysis. Horm Metab Res 2015; 47(9): 643-651. doi: 10.1055/s-0035-1554689
  26. Sharma J, Raggi P, Kutner N et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 2012; 214: 400–407. doi: 10.1016/j.jamcollsurg.2011.12.046
  27. Hiramitsu T, Tominaga Y, Okada M et al. A Retrospective Study of the Impact of Intraoperative Intact Parathyroid Hormone Monitoring During Total Parathyroidectomy for Secondary Hyperparathyroidism: STARD Study. Medicine (Baltimore) 2015;94(29):e1213. doi: 10.1097/MD.0000000000001213
  28. Ivarsson KM, Akaberi S, Isaksson E. et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant 2015;30(12):2027-2033. doi: 10.1093/ndt/gfv334
  29. Ishani A, Liu J, Wetmore JB et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015; 10(1): 90-97. doi: 10.2215/ CJN.03520414
  30. Komaba H, Taniguchi M, Wada A et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 88(2): 350-359. doi: 10.1038/ki.2015.72
  31. Lin HC, Chen CL, Lin HS et al. Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2014; 80(4): 508–515. doi: 10.1111/cen.12333
  32. Goldenstein PT, Elias BM, de Freitas do Carmo LP et al. Parathyroidectomy Improves Survival In Patients with Severe Hyperparathyroidism: A Comparative Study. PLoS One 2013; 8(8): e68870. doi: 10.1371/journal.pone.0068870
  33. Conzo G, Perna AF, Savica V et al. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. BMC Surg 2013; 13 [Suppl 2]: S4. doi: 10.1186/1471-2482-13-S2-S4
  34. Wetmore JB, Liu J, Do TP et al. Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 2016;31(1):103-111. doi: 10.1093/ndt/gfv291
  35. Saito A, Matsumoto Y, Oyama Y et al. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism. Ther Apher Dial 2010;14(1):98103. doi: 10.1111/j.1744-9987.2009.00706.x
  36. Новокшонов КЮ, Карелина ЮВ, Земченков АЮ и др. Результаты скрининга на маркеры минеральных и костных нарушений при хронической болезни почек среди диализных пациентов Северо-Западного Федерального Округа. Нефрология 2016; 20(1):36-50. [Novokshonov KY, Karelina YV, Zemchenkov A et al. Chronic kidney disease mineral and bone disorder markers in screening study among dialysis patients in North-West Federal Region of Russia. Nephrology (in Rus) 2016; 20(1):36-50]
  37. Егшатян ЛВ, Рожинская ЛЯ, Кузнецов НС, Шамхалова МШ. Плейотропные эффекты паратиреоидэктомии и агониста кальций-чувствительного рецептора цинакалцета. Рациональная фармакотерапия в кардиологии 2013; 9(2):152-157. [Egshatyan LV, Rozhinskaya LYa, Kuznetsov NS, Shamkhalova MSh. Pleiotropic effects of parathyroidectomy and agonist calcium-sensitive receptor, cinacalcet. Rational Pharmacotherapy in Cardiology (in Rus) 2013; 9(2):152-157]